Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be another pivotal setback for its pipeline.
Arrowhead has paused its Phase I/II trial of RNAi cystic fibrosis drug ARO-ENaC after a concurrent chronic toxicology study in rats turned up troubling lung inflammation signals, the biotech said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.